LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.”
LISCure is developing the world’s first injectable immuno-oncology program
using non-pathogenic microorganisms. We focus on the development of
first-in-class new drugs against diseases for which existing microbiome treatments
have been rarely attempted.
We are developing therapeutics for diseases with high unmet medical needs, such as immuno-oncology, metabolic diseases, autoimmune diseases, and neurodegenerative diseases, using a single strain and microbial-derived metabolites, extracellular vesicles (EVs) such as exosomes.
To continue providing new treatments for patients, we developed the LMT (LISCure Microbiology-based Technology) platform to discover and identify microorganisms that are scientifically proven safe and effective for various therapeutic areas.
Complete remission with a single dose only
Liver diseases, autoimmune diseases,
Safety assessment (reviewed by FDA)
Using metabolites (such as EV)